CYP3A4 and neoplasm: In the clinical trial of high doses of lapatinib conducted by Moasser and colleagues, it may be that the responses seen with lapatinib and ketoconazole were due to the ability of ketoconazole to inhibit ABCB1 in tumor, and not just CYP3A4 in the intestine [35].